About Arizest Pharma (India) Private Limited
Data last updated:
Arizest Pharma (India) Private Limited is a foreign private limited company based in Bengaluru, Karnataka, India, a subsidiary of Arizest (Singapore) Private Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 11 June 2015 and has been in existence for over 11 years.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U24100KA2015FTC080832. Its GSTIN is 29AANCA5442J1ZA (Karnataka).
The company has an authorised share capital of ₹75 Cr and a paid-up capital of ₹66.34 Cr. It is led by directors including Manorama Avinash and Chinnasamy Anbarasu.
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at No.77D KIADB Industrial Area Jigani, Bengaluru, Karnataka, India – 560100.
As per the financials filed for FY 2025, the company reported a revenue of ₹3.68 Cr, a growth of 1% compared to the previous year. For the same year it recorded a net profit of ₹1.4 Cr (net margin 38%) and EBITDA of ₹2.39 Cr (EBITDA margin 65%). Revenue has grown at a compounded annual rate (CAGR) of 84% over five years.
The company has about 18 employees on its provident fund (EPFO) records.
As per MCA filings, the company has open charges of ₹40 Cr on record. The company has 3 deals on record (2 rights issues, 1 secondary share transfer); the latest was in April 2019. Its 6 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 3 smaller; the largest is Nutra Marck Life Sciences Private Limited with revenue of ₹3.71 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website arizestpharma.com.
Company details
Contact details
Arizest Pharma (India) Private Limited's registered office is in Bengaluru, Karnataka. Its website is arizestpharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressNo.77D KIADB Industrial Area Jigani, Bengaluru, Karnataka, India – 560100
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Arizest Pharma (India) Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Arizest Pharma (India) is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
Financials of Arizest Pharma (India) Private Limited
FY 2025 filings availableArizest Pharma (India) Private Limited reported revenue of ₹3.68 Cr (up 1% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 84% over five years, including 1% growth in the latest year. EBITDA rose 200% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹2.39 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹1.4 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 65% | ||||
| Net Profit Margin | 38% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Arizest Pharma (India) Private Limited, buy the company report.
Board of directors of Arizest Pharma (India) Private Limited
Arizest Pharma (India) has 3 current directors and 9 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Manorama Avinash | Director | 11 Jun 2015 | 11 Years 4 Months | Current |
| Chinnasamy Anbarasu | Director | 06 May 2024 | 2 Years 5 Months | Current |
| Kuppodi Niranjan | Director | 18 Mar 2025 | 1 Years 7 Months | Current |
Peer comparison
Arizest Pharma (India) Private Limited is compared with the 6 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Nutra Marck Life Sciences Private Limited | ₹3.71 Cr (FY 2025) | 0.0% | Karnal, Haryana, India | |||
| Parachem Pharmaceutical Private Limited | ₹3.7 Cr (FY 2025) | 11.0% | Delhi, India | |||
| Gray Anon Formulations Private Limited | ₹3.69 Cr (FY 2025) | -9.0% | Chennai, Tamil Nadu, India | |||
| Arizest Pharma (India) Private Limitedthis company | ₹3.68 Cr (FY 2025) | ₹1.4 Cr | 38% | 1.0% | 18 | Bengaluru, Karnataka, India |
| Prolife Fine and Specialty Chemicals Private Limited | ₹3.67 Cr (FY 2019) | Ahmedabad, Gujarat, India | ||||
| Eshyasi Pharma Limited | ₹3.66 Cr (FY 2024) | -7.0% | Vadodara, Gujarat, India | |||
| Ravi Plant Biotechnologies Limited | ₹3.66 Cr (FY 2025) | 21.0% | Panchmahals, Gujarat, India |
To see the full peer comparison of Arizest Pharma (India) Private Limited, buy the company report.
Auditor
Arizest Pharma (India) Private Limited is audited by Patil Kabbur & Associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Patil Kabbur & Associates | FY 2023 | 015281S |
Shareholding
The shareholding of Arizest Pharma (India) Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Arizest Pharma (India) Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 16 Dec 2020 | 100400243 | Hdfc Bank Limited | ₹40 Cr | Open |
Total charge records: 1 View all charges
Deals & funding
Arizest Pharma (India) Private Limited has 3 deals on record (2 rights issues, 1 secondary share transfer); the latest was in April 2019.
Deals on record (3 of 3)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Apr 2019 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Apr 2018 | Rights issue | ₹57.09 Cr | Investors: Arizest (Singapore) Private Limited |
| Sep 2016 | Rights issue | ₹7.26 Cr | Investors: Arizest (Singapore) Private Limited |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Arizest Pharma (India) Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Arizest Pharma (India) Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Arizest Pharma (India) Private Limited has a workforce of 18 employees on its EPFO records as of Apr 05, 2024, across 1 active EPFO establishment.
GST
Arizest Pharma (India) has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AANCA5442J1ZA | Karnataka | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Arizest Pharma (India) Private Limited, buy the company report.
Recent activity
Arizest Pharma (India) Private Limited has 9 board changes on record since 2015: 3 appointments and 6 cessations. The latest: Kuppodi Niranjan ceased to be Additional Director on 28 Sep 2025.
1 earlier event is in the company report.
Frequently asked questions
Arizest Pharma (India) is an active foreign private limited company based in Bengaluru, Karnataka, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 11 June 2015 (11+ years old) and is registered under CIN U24100KA2015FTC080832.
Arizest Pharma (India) has 3 current directors:
- Manorama Avinash - Director
- Chinnasamy Anbarasu - Director
- Kuppodi Niranjan - Director
The latest financial statements of Arizest Pharma (India) on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 29 September 2025. Year-wise statements from FY 2016 are in the company report.
The GSTIN of Arizest Pharma (India) is 29AANCA5442J1ZA, registered in Karnataka.
The CIN (Corporate Identification Number) of Arizest Pharma (India) is U24100KA2015FTC080832. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Arizest Pharma (India) was incorporated on 11 June 2015, making it 11+ years old. It is registered with the Registrar of Companies, Bangalore.
Arizest Pharma (India) has 3 deals on record (2 rights issues, 1 secondary share transfer); the latest was in April 2019.
The peers of Arizest Pharma (India) by revenue are Nutra Marck Life Sciences Private Limited, Parachem Pharmaceutical Private Limited, Gray Anon Formulations Private Limited, Prolife Fine and Specialty Chemicals Private Limited, Eshyasi Pharma Limited and 1 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Kuppodi Niranjan ceased to be Additional Director on 28 Sep 2025. Kuppodi Niranjan was appointed as Director on 18 Mar 2025. Chinnasamy Anbarasu ceased to be Additional Director on 29 Sep 2024. Arizest Pharma (India) has 9 board changes on record in total.
Arizest Pharma (India) can be reached through the website arizestpharma.com. Its registered office is in Bengaluru, Karnataka, India.
The registered office of Arizest Pharma (India) is at No.77D KIADB Industrial Area Jigani, Bengaluru, Karnataka, India – 560100.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
